Philip Morris Matches Estimates but ZYN Pricing Shift Pressures U.S. Profit
Philip Morris beat third-quarter adjusted EPS expectations, but its full-year currency-neutral outlook did not improve, implying the upside came from the fourth quarter. U.S. ZYN shipments rose 4.2%, while a shift to larger cans at the same price will reduce revenue per pouch by about 25%. The company expects U.S. operating income to fall to roughly break-even or below in the fourth quarter as promotional spending rises.
Philip Morris reported Q3 adjusted EPS of $2.36 versus $2.29 consensus, but its currency-neutral full-year outlook was unchanged. After subtracting $6.52 earned through September, implied Q4 EPS falls to $1.77–$1.92 from $1.90–$2.00, suggesting the beat was offset by a softer final quarter.
U.S. ZYN shipments reached 3.2 billion pouches, up 4.2%. Starting in October, PMI will put most flagship ZYN into 20-pouch cans rather than 15-pouch cans without changing price, reducing revenue per pouch by roughly a quarter. U.S. SG&A was about $370 million in Q3 and may rise 10% in Q4; U.S. operating income was $171 million and could approach zero or turn slightly negative.
The ZYN pricing and promotion reset could affect adult nicotine users through larger packages and lower revenue per pouch, while higher promotional spending may influence retailer stocking and availability. A weaker U.S. profit contribution may shape investor views on tobacco harm-reduction products, potentially affecting capital allocation and jobs tied to U.S. distribution. If demand shifts, retailers, workers, and public-health observers could feel the effects.